Correction to "Clinical application of flow cytometry in patients with unexplained cytopenia and suspected myelodysplastic syndrome: A report of the European LeukemiaNet International MDS-Flow ...

SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease recurrence when they received the bispecific T-cell engager ...

Using CD22/CD19 CAR T-cell therapy followed by autologous stem cell transplant (ASCT) showed promising results in patients with Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic ...

B-cell acute lymphoblastic leukemia is the most common form of childhood cancer. In this type of cancer, which affects blood ...

Obe-cel is the first FDA-approved CAR T-cell therapy for B-ALL without a REMS requirement, based on the FELIX trial's positive outcomes. The FELIX trial reported a 63% complete remission rate, with 42 ...

A multicenter, single-arm, phase 2 trial investigated the activity and safety of varnimcabtagene autoleucel in adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

A combination of two drugs could improve outcomes and reduce the need for toxic chemotherapy for B-cell acute lymphoblastic leukemia (B-ALL), the commonest cancer in childhood and one that can be ...

Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women With Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial Studying 767 children ...